AEON Biopharma Faces Delisting Concerns
Ticker: AEON · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1837607
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
AEON Biopharma might get delisted, check their listing status ASAP.
AI Summary
AEON Biopharma, Inc. filed an 8-K on February 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company was formerly known as Priveterra Acquisition Corp. and changed its name on December 22, 2020.
Why It Matters
This filing indicates potential issues with AEON Biopharma's continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's operations and stock value.
Key Players & Entities
- AEON Biopharma, Inc. (company) — Registrant
- Priveterra Acquisition Corp. (company) — Former company name
- February 3, 2025 (date) — Date of earliest event reported
- February 7, 2025 (date) — Filing date
- December 22, 2020 (date) — Date of name change
FAQ
What specific listing rule or standard has AEON Biopharma, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that AEON Biopharma, Inc. has failed to satisfy, only that a notice has been issued.
What is the current status of AEON Biopharma, Inc.'s listing on its exchange?
The filing indicates a notice of delisting or failure to satisfy a continued listing rule, suggesting the company is at risk of being delisted.
When was AEON Biopharma, Inc. formerly known as Priveterra Acquisition Corp.?
AEON Biopharma, Inc. was formerly known as Priveterra Acquisition Corp. until December 22, 2020.
What is the principal executive office address for AEON Biopharma, Inc.?
The principal executive offices are located at 5 Park Plaza, Suite 1750, Irvine, CA 92614.
What is the SIC code for AEON Biopharma, Inc.?
The Standard Industrial Classification (SIC) code for AEON Biopharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 851 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2025-02-07 16:07:29
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share AEON NYSE Ameri
- $2.0 million — which requires stockholders' equity of $2.0 million or more if the listed company has repor
- $32.1 million — any reported a stockholders' deficit of $32.1 million at September 30, 2024 and has had losse
Filing Documents
- aeon-20250203x8k.htm (8-K) — 43KB
- aeon-20250203xex99.htm (EX-99) — 16KB
- aeon-20250203xex99001.jpg (GRAPHIC) — 4KB
- 0001837607-25-000010.txt ( ) — 199KB
- aeon-20250203.xsd (EX-101.SCH) — 4KB
- aeon-20250203_def.xml (EX-101.DEF) — 3KB
- aeon-20250203_lab.xml (EX-101.LAB) — 17KB
- aeon-20250203_pre.xml (EX-101.PRE) — 10KB
- aeon-20250203x8k_htm.xml (XML) — 5KB
01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 3, 2025, AEON Biopharma, Inc. (the "Company" or "AEON") received a written notice of non-compliance (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with continued listing standards of Section 1003(a)(i) of the NYSE American Company Guide (the "Company Guide"), which requires stockholders' equity of $2.0 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years (the "Minimum Requirement"), as defined in Section 1003(a)(i) of the Company Guide. Pursuant to the Notice, the Company reported a stockholders' deficit of $32.1 million at September 30, 2024 and has had losses in the two most recent fiscal years ended December 31, 2023 based on the Company's Annual Report on Form 10-K/A filed with the U.S. Securities and Exchange Commission on May 14, 2024, and the Company is not currently eligible for any exemption from the stockholders' equity requirement in Section 1003(a) of the Company Guide, and as such, the NYSE American deems the Company below compliance with the Minimum Requirement. The Notice has no immediate effect on the listing of the Company's listing on the NYSE American. The Company has been provided with a compliance period of 18 months to regain compliance with the Minimum Requirement. To regain compliance, the Company must submit a plan by March 5, 2025, advising of actions taken or will be taken to regain compliance with the continued listings standards of the Company Guide by August 3, 2026 (the "Plan"). The Plan will be subject to approval and periodic reviews by the NYSE American to monitor compliance with the Plan. If the Company does not submit a plan or if the Plan is not accepted, or if the Plan is accepted but the Company is not in compliance with the Minimum Requirement by
01. Financial Statement and Exhibits
Item 9.01. Financial Statement and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated February 7, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AEON Biopharma, Inc. Date: February 7, 2025 By: /s/ Marc Forth Marc Forth Chief Executive Officer